Gilead Sciences, IncNasdaq: GILD
Health Care · Biotechnology
$131.80
+0.73%
Vol: 3.1M
Research Digest
Friday, May 1, 2026
Gilead completes $7.8B Arcellx acquisition and receives FDA priority review for bictegravir+lenacapavir HIV drug
Gilead completed acquisition of Arcellx on April 28 for $115/share plus $5 CVR (~$7.8B total), gaining full control of anito-cel CAR T-cell therapy for multiple myeloma. FDA granted priority review for once-daily bictegravir 75mg/lenacapavir 50mg HIV combination. Expected Q1 2026 earnings release May 7. Multiple product launches anticipated 2026-2027 including bulevirtide (Q2 2026), Trodelvy, anito-cel (PDUFA Dec 23), and bictegravir+lenacapavir.
Previous Market Intelligence
13 daysApr 30Gilead completes $7.8B Arcellx acquisition for CAR-T leader; plans $3B Tubulis oncology dealPositive▶
Gilead completed its acquisition of Arcellx on April 28 at $115 per share in cash plus $5 per share CVR, representing ~$7.8B implied equity value. The deal provides Gilead with full control of anitocabtagene autoleucel (anito-cel), an investigational BCMA-directed CAR-T therapy for multiple myeloma, strengthening its oncology pipeline. Additionally, Gilead is acquiring German biotech Tubulis for >$3 billion to expand ADC (antibody-drug conjugate) capabilities. CEO Daniel O'Day sold 10,000 shares post-close. Gilead plans to report Q1 2026 results May 7. Analyst Jefferies maintains Buy with $180 PT. Barron's notes GILD crossed a breakout level with 35% upside potential. M&A activity signals aggressive portfolio modernization despite near-term integration risks.
Apr 29Gilead completes $7.8B Arcellx acquisition; also buying Tubulis for $3B+ to expand oncology pipelinePositive▶
Gilead Sciences completed acquisition of Arcellx on April 28, 2026 for $115/share cash plus $5 contingent value right, representing $7.8B total equity value. Deal grants Gilead full control of anitocabtagene autoleucel (anito-cel), an investigational BCMA-directed CAR T-cell therapy for multiple myeloma targeting commercial launch. Additionally, Gilead is acquiring German biotech Tubulis for $3B+ to expand its oncology pipeline with antibody-drug conjugate (ADC) technologies. FDA accepted NDA for HIV combination treatment (bictegravir/lenacapavir) with priority review action date 8/27/26. Expanding lenacapavir HIV prevention access via multi-year collaboration with State Dept, PEPFAR, Global Fund targeting 1M+ additional patients. Analyst price targets range $123-$180.
Apr 16Gilead acquires oncology biotech Tubulis for $5 billion to strengthen antibody-drug conjugate pipeline ahead of extended Arcellx tender offerPositive▶
Gilead Sciences announced a definitive agreement to acquire Tubulis GmbH for $3.15 billion upfront plus up to $1.85 billion in contingent milestone payments, expected to close in Q2 2026. Tubulis lead asset, TUB-040, is in Phase 1b/2 for platinum-resistant ovarian cancer and NSCLC. Gilead also extended its tender offer for Arcellx to April 24, 2026. Morgan Stanley maintained Overweight and raised its price target from $171 to $175. Scotiabank reaffirmed Buy on April 13, and Citi raised its target to $165 from $156. Based on 41 analysts, GILD has a Strong Buy consensus with a median price target of $160.
Apr 14Gilead acquires Tubulis for $3B to strengthen antibody-drug conjugate pipelinePositive▶
Acquiring Tubulis for $3B+ adding ADC assets for oncology. Citigroup raised PT to $165, Jefferies to $180. Combined with Arcellx and Ouro acquisitions.
Apr 13Tubulis acquisition for up to $5B expanding oncology deal spreePositive▶
Gilead agreed to acquire German biotech Tubulis for up to $5B ($3.15B upfront + $1.85B milestones) to expand oncology pipeline with antibody-drug conjugates. Expected close Q2 2026. Part of major acquisition strategy including Arcellx and Ouro Medicines. Stock trading ~$138.99 with strong analyst support.
Apr 10Gilead acquires Tubulis for $5B; expands ADC oncology pipeline with strategic collaborations.Positive▶
Gilead agreed to acquire German biotech Tubulis for up to $5 billion ($3.15B upfront, $1.85B in milestones) to boost its antibody-drug conjugate cancer drug portfolio. Also expanded collaboration with Tempus AI for oncology pipeline and exercised options to license KT-200 from Kymera Therapeutics. Truist raised price target to $155 from $152.
Apr 9Gilead Sciences Announces $5 Billion Acquisition of German Cancer Biotech TubulisPositive▶
Gilead Sciences agreed to acquire German biotech Tubulis GmbH in a $5 billion deal ($3.15B upfront plus $1.85B in milestone payments). The acquisition expands Gilead's oncology pipeline with antibody-drug conjugate (ADC) technology. This is the third major deal in Gilead's $15B acquisition spree, following the $7.8B Arcellx purchase. Truist raised price target to $155 from $152 with Buy rating.
Apr 8Gilead acquires Tubulis for $5B to boost oncology ADC pipeline; Arcellx tender extended to April 24.Positive▶
Gilead announced $5 billion acquisition of Tubulis GmbH (German clinical-stage biotech): $3.15B upfront + $1.85B milestones. Also acquiring Ouro Medicines ($1.7B upfront + $500M milestones) for BCMAxCD3 T cell engager. Extended Arcellx tender offer to April 24 at $115/share + $5 CVR. Stock up 24.5% in 6 months. RBC raised target to $123 from $118.
Apr 7Gilead raises acquisition offer to $115/share for Arcellx plus $5 CVR, extends tender to April 24Positive▶
Gilead Sciences pursuing strategic acquisitions: extended tender offer for Arcellx at $115/share cash plus $5 contingent value right (payable 2029 if sales targets met), tender expiration extended to April 24, 2026. Galapagos binding agreement entered with Gilead. Stock up 24.5% over six months; current price $139.50. Q1 2026 EPS projected $8.66 (+6.3% YoY). Analyst consensus: 22 Strong Buys, 2 Moderate Buys, 8 Holds with PT $158.86. Strong HIV market position and expanding oncology pipeline. UBS affirms Buy citing Yeztugo sales up 56% month-over-month in February.
Apr 6Gilead to acquire Arcellx for $7.8B; positive Phase 3 Trodelvy/Keytruda TNBC data.Positive▶
Gilead agreed to acquire Arcellx at $115/share + $5 CVR (~$7.8B equity). NEJM published positive Phase 3 data: Trodelvy + Keytruda reduced disease progression/death risk 35% in first-line PD-L1+ TNBC. Once-daily HIV regimen bictegravir/lenacapavir maintained suppression through Week 48.
Apr 3Gilead acquires Ouro Medicines for $2.2B; strategic M&A boosts immunology portfolio amid strong analyst support.Positive▶
Gilead announced March 31 definitive agreement to acquire Ouro Medicines for ~$2.2B, adding a clinical-stage BCMAxCD3 T cell engager for autoimmune conditions. Prior Arcellx acquisition ($7.8B) for cancer therapy also contributed. Q4 2025: revenue $7.9B, adjusted EPS $1.86 (both beat consensus). FY26 guidance: $8.45-8.85 EPS. 22 of 32 analysts rate Strong Buy with $158.86 PT. Overnight: down 1.13% but strong M&A narrative supports long-term thesis.
Apr 1Gilead acquires Ouro Medicines for $2.2B to lead immune reset revolution; second major acquisition in one month.Positive▶
Gilead announced definitive agreement to acquire Ouro Medicines for $2.175 billion on March 23, 2026, its second major immunology investment within a month following the $7.8 billion Arcellx acquisition. Ouro's lead candidate gamgertamig targets functional cures through immune reset approach. Gilead reported 2025 revenue of $29.4B with Biktarvy sales reaching $14.3B. 2026 guidance: product sales $29.6-$30.0B. Stock rose 3.62% to $137.34. Dividend increased 3.8% to $0.82.
Mar 31Gilead to acquire Arcellx for $7.8B and Ouro Medicines for $2B+ to expand oncology and immunology.Positive▶
Gilead acquiring Arcellx for $7.8B total and Ouro Medicines for $2B+. Phase 3 ARTISTRY data showed HIV efficacy at Week 48. FDA approved Yeztugo. Stock down 4.40% week. Jefferies Buy with $180 target.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| ABBVABBVIE | $207.05 | -2.02% | +2.2% | 13.1x | — | $373.8B |
| AMGNAMGEN | $330.27 | -4.62% | +1.1% | 14.8x | 0.47 | $186.7B |
| GILDGILEAD | $131.80 | +0.73% | -6.6% | 13.6x | 0.40 | $162.4B |
| VRTXVERTEX | $425.02 | -0.55% | -1.6% | 19.6x | 0.37 | $108.7B |
| REGNREGENERON | $702.19 | -0.69% | -7.3% | 13.0x | 0.40 | $74.1B |
| BIIBBIOGEN | $187.16 | -1.12% | +9.8% | 11.9x | 0.16 | $27.9B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price between 50d and 200d. Testing 50d support.